Amirhossein Ramezani Ahmadi

Amirhossein Ramezani Ahmadi

Auto-generated profile, based on publicly available information

Amirhossein Ramezani Ahmadi

Isfahan Endocrine and Metabolism Research Center, Isfahan University of Medical Sciences, Isfahan, Iran

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
8 October 2023 in Food Science & Nutrition
Verified
Journal Article
Open access
NMNava Morshedzadeh
Nava Morshedzadeh
AAAmirhossein Ramezani Ahmadi
Amirhossein Ramezani Ahmadi
VBVahideh Behrouz
Vahideh Behrouz
EMElias Mir
Elias Mir
Insulin resistance, oxidative stress, hyperlipidemia, and inflammation play main roles in the development of nonalcoholic fatty liver disease (NAFLD). Some studies have reported that hesperidin can reduce hyperglycemia and hyperlipidemia by inhibiting inflammatory pathways. In the current study, our purpose was to evaluate whether it can influence the primary parameters in NAFLD and improve the treatment effectiveness for future trials. Various studies have found that hesperidin involves multiple signaling pathways such as cell proliferation, lipid and glucose metabolism, insulin resistance, oxidative stress, and inflammation, which can potentially affect NAFLD development and prognosis. Recent findings indicate that hesperidin also regulates key enzymes and may affect the severity of liver fibrosis. Hesperidin inhibits reactive oxygen species production that potentially interferes with the activation of transcription factors like nuclear factor‐κB. Appropriate adherence to hesperidin may be a promising approach to modulate inflammatory pathways, metabolic indices, hepatic steatosis, and liver injury.

1 January 2019 in Clinical Nutrition Research
Verified
Journal Article
Open access
PDF file
NHNazila Hasaniani
Nazila Hasaniani
MRMehran Rahimlou
Mehran Rahimlou
AAAmirhossein Ramezani Ahmadi
Amirhossein Ramezani Ahmadi
AKAlireza Mehdizadeh Khalifani
Alireza Mehdizadeh Khalifani
MAMohammad Alizadeh
Mohammad Alizadeh
Hasaniani N, et al. Clin Nutr Res. 2019 Oct;8(4):284-295. https://doi.org/10.7762/cnr.2019.8.4.284

1 November 2023 in Endocrine Connections
Verified
Journal Article
Open access
PDF file
BABehnaz Abiri
Behnaz Abiri
MVMajid Valizadeh
Majid Valizadeh
AAAmirhossein Ramezani Ahmadi
Amirhossein Ramezani Ahmadi
SAShirin Amini
Shirin Amini
MNMohammad Nikoohemmat
Mohammad Nikoohemmat
FHFarhad Hosseinpanah
Farhad Hosseinpanah
Objectives: It has not been established whether vitamin D deficiency is associated with anthropometric state; therefore, this systematic review examined the relationship between serum vitamin D levels with anthropometrics and adiposity across different ages. Methods: Studies that examined vitamin D deficiency with adiposity measures in different age groups were searched in the PubMed, Scopus, EMBASE, and Google Scholar databases until November 2023. Two investigators independently reviewed titles and abstracts, examined full-text articles, extracted data, and rated the quality in accordance with the Newcastle-Ottawa criteria. Results: Seventy-two studies, with a total of 59,430 subjects, were included. Of these studies, 27 cross-sectional studies and one longitudinal study (with 25,615 participants) evaluated the possible link between 25(OH)D serum concentrations and anthropometric/adiposity indices in the pediatric population. Forty-two cross-sectional studies and two cohort investigations (with 33,815 participants) investigated the relationship between serum 25(OH)D levels and adiposity measures in adults and/or the elderly population. There is evidence supporting links between vitamin D deficiency and obesity, and revealed an inverse association between vitamin D and adiposity indicators, specifically in female subjects. However, the effects of several confounding factors should also be considered. Conclusion: Most published studies, most of which were cross-sectional, reported a negative association between vitamin D and female adiposity indicators. Therefore, serum vitamin D levels should be monitored in overweight/obese individuals.

24 October 2022 in Clinical Nutrition Research
Verified
Journal Article
Open access
PDF file
BABehnaz Abiri
Behnaz Abiri
AAAmirhossein Ramezani Ahmadi
Amirhossein Ramezani Ahmadi
MHMahdi Hejazi
Mahdi Hejazi
SAShirin Amini
Shirin Amini
Abiri B, et al. Clin Nutr Res. 2022 Oct;11(4):331-346. https://doi.org/10.7762/cnr.2022.11.4.331

26 December 2023 in Expert Review of Endocrinology & Metabolism
Verified
Journal Article
Closed access
MYMaryam Yavari
Maryam Yavari
MAMojtaba Akbari
Mojtaba Akbari
AAAmirhossein Ramezani Ahmadi
Amirhossein Ramezani Ahmadi
MDMansour Siavash Dastjerdi
Mansour Siavash Dastjerdi
MHMaryam Sadat Hashemi
Maryam Sadat Hashemi
BackgroundThis study aimed to systematically review the effect of selenium and inositol combination on thyroid function, autoimmune characteristics in thyroid diseases.Research design and methodsTo identify eligible studies, a systematic search was conducted in the PubMed/MEDLINE, Science-Direct, CINHAL, EMBASE, SCOPUS, Psychinfo, Cochrane, ProQuest, and Web of Science were searched using the main concepts, and all English-written articles that were published between 2007 and 2022 and had an available full text were examined.ResultsThe data analysis of this research revealed that after the simultaneous use of selenium and inositol supplements, the level of Triiodothyronine(T3) increased by 0.105 in patients with thyroid disorders although this increase was not significant (P-value: 0.228). The level of Thyroxine (T4) significantly increased by 0.06 (P-value: 0.04). Anti-Thyroid Peroxidase Antibody (TPOAb) titer decreased by 119.36%, which was not significant (P-value: 0.070). Finally, the level of Thyroid-stimulating hormone (TSH) decreased by 1.45%, which was a significant change (P-value: 0.001).ConclusionIt was observed that simultaneous use of selenium and inositol supplements did not change the T3 and TPOAb titer levels; however, it leads to a decrease in TSH and increase in T4 levels. Further studies are required due to the limited number of studies.

25 February 2025 in Immunopathologia Persa
Verified
Journal Article
Open access
PDF file
AMAtousa Masoud
Atousa Masoud
MAMojtaba Akbari
Mojtaba Akbari
LALida Jamal Ashini
Lida Jamal Ashini
RARoya Adelnia
Roya Adelnia
PSParisa Khodabandeh Shahraki
Parisa Khodabandeh Shahraki
APAghileh Panahi
Aghileh Panahi
Introduction: The NLRP3 inflammasome plays a key role in the regulation of inflammation and has been implicated in various inflammatory diseases. The present study evaluated the impact of MCC950 on NLRP3 and inflammatory biomarkers in systematic review and meta-analysis. Methods: Searches were performed across databases including Medline (PubMed), Scopus, Web of Science, and Embase. The pooled effects of MCC950 on NLRP3, TNF-alpha, interleukin (IL)-16, IL-18, and IL-1β were analyzed using a random effects model. Results: Twenty animal studies met the inclusion criteria. MCC950 did not significantly reduce NLRP3 (SMD=-0.88; 95% CI: -1.79,0.03; P=0.058) and TNF-alpha levels (SMD= -1.18; 95% CI: -2.45, 0.09; P=0.069). A significant reduction was observed in IL-18 (SMD= -1.22; 95% CI: -2.44, -0.00; P=0.049), IL-16 (SMD= -1.225; 95% CI: -2.779, 0.329; P=0.122) and IL-1β (SMD=-1.38; 95% CI: -2.44 to -0.32; P=0.011) concentrations after MCC950 treatment. Conclusion: MCC950 reduced serum levels of some inflammatory factors. However, NLRP3 did not change significantly. Further research is necessary to understand the function of pharmacological inhibition of NLRP3 activation. Registration: This study was conducted in accordance with the PRISMA checklist, and its protocol was registered on both the PROSPERO website (ID: CRD42024567477) and the Research Registry website (UIN: reviewregistry1887).